Security key
558868105
MADRIGAL PHARMACEUTICALS, INC. - Common Stock (MDGL)
CUSIP: 558868105
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 23,561,031
- Total 13F value
- $13,715,196,817
- Share change
- +198,837
- Put/Call ratio
- 84%
- SEC-reported price per share
- $582.34
- Number of holders
- 385
- Value change
- +$154,180,477
- Number of buys
- 207
- Number of sells
- 155
- Shares outstanding
- 23,203,174
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
385
Top holders
10
MDGL full security history
Ownership snapshot
Full 13F holder table
MADRIGAL PHARMACEUTICALS, INC. SEC filings
MADRIGAL PHARMACEUTICALS, INC. company facts
Broader feeds
Ownership snapshot
Top reported holders of MDGL - MADRIGAL PHARMACEUTICALS, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Paul A. Friedman
Disclosed value leader
Paul A. Friedman
Comparable rows
15/15
Latest evidence
10 Dec 2025
13D/G
3/4/5
13F
Lead comparable stake: 7.8%
13D/G row: Paul A. Friedman
Showing 1-6 of 15 holder rows.
Quick read
Paul A. Friedman leads the comparable SEC ownership view at 7.8%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Paul A. Friedman's linked filing trail.
Comparable ownership
Top 5
Paul A. Friedman
7.8%
Rebecca Taub
7.8%
Kenneth Bate
0.01%
BAKER BROS. ADVISORS LP
9.2%
RTW INVESTMENTS, LP
8.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Paul A. Friedman |
13D/G
Paul A Friedman, M.D.
|
7.8%
|
$982,730,986
1,814,831 shares
|
$0 | 10 Dec 2025 |
| Rebecca Taub |
13D/G
Rebecca Taub, M.D.
|
7.8%
|
$982,730,986
1,814,831 shares
|
$0 | 10 Dec 2025 |
| Kenneth Bate |
3/4/5
Director
|
0.01%
|
$1,289,808
2,627 shares
|
-$11,679,363 | 05 Nov 2025 |
| BAKER BROS. ADVISORS LP |
13F
Company
|
9.2%
|
$982,312,581
2,141,701 shares
|
— | 30 Sep 2025 |
| RTW INVESTMENTS, LP |
13F
Company
|
8.6%
|
$914,424,479
1,993,687 shares
|
— | 30 Sep 2025 |
| PAULSON & CO. INC. |
13F
Company
|
8.2%
|
$874,904,499
1,907,523 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
385
Shares
23,561,031
Rows available
385
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
352
Q4 2025 holders
385
Holder diff
33
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|